Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 7Active not recruiting 5Completed 4Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 1Locally Advanced Rectal Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × peposertib × Clear all
NCT03724890 2025-04-10

Study of Avelumab-M3814 Combinations

EMD Serono

Phase 1 Completed
57 enrolled 56 charts
Tumor-Agnostic

Neoplasms

NCT02516813 2024-10-15

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

EMD Serono

Phase 1 Completed
52 enrolled 43 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03770689 2023-03-21

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

EMD Serono

Phase 1/2 Completed
19 enrolled 21 charts
Gastrointestinal

Locally Advanced Rectal Cancer

NCT02316197 2020-04-28

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
31 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡